The Current Ratio as of November 2024 (TTM) for Bicycle Therapeutics plc (BCYC) is 17.13

According to Bicycle Therapeutics plc’s latest financial reports and current stock price. The company's current Current Ratio is 17.13. This represents a change of 35.94% compared to the average of 12.60 of the last 4 quarters.

Bicycle Therapeutics plc (BCYC) Historical Current Ratio (quarterly & annually)

How has BCYC Current Ratio performed in the past?

The mean historical Current Ratio of Bicycle Therapeutics plc over the last ten years is 8.17. The current 17.13 Current Ratio has changed 20.88% with respect to the historical average. Over the past ten years (40 quarters), BCYC's Current Ratio was at its highest in in the September 2024 quarter at 17.13. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Bicycle Therapeutics plc (BCYC) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Bicycle Therapeutics plc Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Bicycle Therapeutics plc (BCYC) Average Current Ratio

How has BCYC Current Ratio performed in the past?

The current Current Ratio of Bicycle Therapeutics plc (BCYC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Bicycle Therapeutics plc (BCYC) Current Ratio vs. Peers

How is BCYC’s Current Ratio compared to its peers?

Bicycle Therapeutics plc’s Current Ratio is less than IDEAYA Biosciences, Inc. (22.93), greater than AnaptysBio, Inc. (10.23), greater than MeiraGTx Holdings plc (2.34), less than Keros Therapeutics, Inc. (19.03), greater than Homology Medicines, Inc. (4.19), greater than Tenaya Therapeutics, Inc. (5.27), greater than IGM Biosciences, Inc. (5.22), greater than Monte Rosa Therapeutics, Inc. (6.03), greater than Stoke Therapeutics, Inc. (5.09), greater than Merus N.V. (8.32), greater than Inhibrx Biosciences, Inc. (4.70), greater than immatics biotechnologies GmbH (3.98), less than Seer, Inc. (18.36), greater than ORIC Pharmaceuticals, Inc. (13.15), greater than Anebulo Pharmaceuticals, Inc. (3.45), less than Cullinan Oncology, Inc. (24.46), greater than C4 Therapeutics, Inc. (6.31), greater than Adagene Inc. (2.50), greater than Acrivon Therapeutics, Inc. Common Stock (12.75), greater than Mineralys Therapeutics, Inc. (8.55),

Build a custom stock screener for Bicycle Therapeutics plc (BCYC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bicycle Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Bicycle Therapeutics plc (BCYC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Bicycle Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.